Key clinical point: Galcanezumab improves functioning and decreases disability in patients with treatment-resistant migraine.
Main finding: At month 3, galcanezumab vs. placebo caused a greater improvement in the Migraine-Specific Quality of Life Questionnaire (version 2.1 Role Function-Restrictive) (least-squares mean [LSM] change 23.19 vs. 10.66; P ≤ .0001] and European Quality of Life-5 Dimensions-5 Level Visual Analog Scale (LSM change 3.38 vs. −0.086; P = .0277) scores and a greater reduction in Migraine Disability Assessment total scores (LSM chang, −21.10 vs. −3.30; P ≤ .0001).
Study details: Findings are from the phase 3b CONQUER trial including 462 adult patients with episodic or chronic migraine and no response to previous 2-4 migraine preventive treatment categories who were randomly assigned to double-blind treatment with galcanezumab (n = 232) or placebo (n = 230) for 3 months followed by 3-month open-label treatment with galcanezumab.
Disclosures: Eli Lilly and Company sponsored the study. SJ Tepper and J Ailani declared receiving research grants, speaker's/advisory board member's honoraria, or institutional research funding for clinical trials from various sources, including Eli Lilly. The rest of the authors are employees and stockholders of Eli Lilly.
Source: Tepper SJ et al. Clin Drug Investig. 2022 ( Jan 18). Doi: 10.1007/s40261-021-01115-5